[
  {
    "ts": null,
    "headline": "Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks",
    "summary": "Hims & Hers Health, Eli Lilly, and Novo Nordisk shares all slid Thursday after Hims & Hers said it would start selling a compounded weight-loss pill, at a lower price than rivals.",
    "url": "https://finnhub.io/api/news?id=57e34dc13c632e176e0094e3df70585246b08d9e4a078c62bed932430bf20192",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770325899,
      "headline": "Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks",
      "id": 138369791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health, Eli Lilly, and Novo Nordisk shares all slid Thursday after Hims & Hers said it would start selling a compounded weight-loss pill, at a lower price than rivals.",
      "url": "https://finnhub.io/api/news?id=57e34dc13c632e176e0094e3df70585246b08d9e4a078c62bed932430bf20192"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Just Delivered Fantastic News to Shareholders",
    "summary": "The stock price has climbed in the triple digits over three years.",
    "url": "https://finnhub.io/api/news?id=7a80bc228a56a5ad3c9f06a2295c704f428aefba3e81c52037ec378cadbf6f13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770319800,
      "headline": "Eli Lilly Just Delivered Fantastic News to Shareholders",
      "id": 138367478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock price has climbed in the triple digits over three years.",
      "url": "https://finnhub.io/api/news?id=7a80bc228a56a5ad3c9f06a2295c704f428aefba3e81c52037ec378cadbf6f13"
    }
  },
  {
    "ts": null,
    "headline": "Lilly stops development of three drugs, including gene therapy",
    "summary": "Eli Lilly has terminated the development of a gene therapy, an anti-CD19 antibody and a radioligand therapy.",
    "url": "https://finnhub.io/api/news?id=025baab3bae63bfdfbe4beb80b0a00c067688847ec0eab338bd17df4e6b28d4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770317356,
      "headline": "Lilly stops development of three drugs, including gene therapy",
      "id": 138367479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has terminated the development of a gene therapy, an anti-CD19 antibody and a radioligand therapy.",
      "url": "https://finnhub.io/api/news?id=025baab3bae63bfdfbe4beb80b0a00c067688847ec0eab338bd17df4e6b28d4c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers offers cheaper weight-loss pill in a shock to Novo",
    "summary": "STORY: Shares of Novo Nordisk plunged again on Thursday after online telehealth firm Hims & Hers said it will offer a compounded version of Novo's new Wegovy weight-loss pill at about $100 less than the brand name price.:: Hims & Hers handoutNovo said it would take legal action against Hims & Hers following that announcement.Hims said it would offer a $49 one-month introductory price for the compounded weight-loss pill and that the price will rise to $99 a month for those who purchase a five-month plan and pay upfront. The price is higher for a three-month subscription.:: Hims & Hers handoutThe announcement came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its forecast, sending its shares down 17%.Novo, like rival Eli Lilly, has been forced to cut prices in the U.S., its biggest market, under pressure from  President Donald Trump.It launched its Wegovy pill last month at a discount to the injection to lure customers who pay directly on its website.:: Novo NordiskNovo and Hims had a partnership in 2025 allowing Hims to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed copycats of Wegovy. Hims accused Novo of attempting to control how its clinicians make decisions.Hims' compounded copy of the Wegovy pill is made from semaglutide, the same active ingredient as the one from Novo.:: Hims & Hers handoutBut the Food and Drug Administration in September issued a warning regarding its marketing of the drug, stating claims like \"same active ingredient as Ozempic and Wegovy\" are misleading, as compounded drugs are not FDA-approved.In a statement released Thursday, Novo Nordisk said, \"The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety,\" adding that it would take action to \"protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework.\"",
    "url": "https://finnhub.io/api/news?id=cc9380cf7f58d73b7884ab38789ec74dd9cc5b451116cfdb2a98c5be0f3a942a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770315348,
      "headline": "Hims & Hers offers cheaper weight-loss pill in a shock to Novo",
      "id": 138367480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Shares of Novo Nordisk plunged again on Thursday after online telehealth firm Hims & Hers said it will offer a compounded version of Novo's new Wegovy weight-loss pill at about $100 less than the brand name price.:: Hims & Hers handoutNovo said it would take legal action against Hims & Hers following that announcement.Hims said it would offer a $49 one-month introductory price for the compounded weight-loss pill and that the price will rise to $99 a month for those who purchase a five-month plan and pay upfront. The price is higher for a three-month subscription.:: Hims & Hers handoutThe announcement came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its forecast, sending its shares down 17%.Novo, like rival Eli Lilly, has been forced to cut prices in the U.S., its biggest market, under pressure from  President Donald Trump.It launched its Wegovy pill last month at a discount to the injection to lure customers who pay directly on its website.:: Novo NordiskNovo and Hims had a partnership in 2025 allowing Hims to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed copycats of Wegovy. Hims accused Novo of attempting to control how its clinicians make decisions.Hims' compounded copy of the Wegovy pill is made from semaglutide, the same active ingredient as the one from Novo.:: Hims & Hers handoutBut the Food and Drug Administration in September issued a warning regarding its marketing of the drug, stating claims like \"same active ingredient as Ozempic and Wegovy\" are misleading, as compounded drugs are not FDA-approved.In a statement released Thursday, Novo Nordisk said, \"The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety,\" adding that it would take action to \"protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework.\"",
      "url": "https://finnhub.io/api/news?id=cc9380cf7f58d73b7884ab38789ec74dd9cc5b451116cfdb2a98c5be0f3a942a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands GLP-1 Capacity While Building Beyond Obesity And Diabetes",
    "summary": "Eli Lilly (NYSE:LLY) is committing over $3.5b to a new manufacturing facility in Pennsylvania’s Lehigh Valley focused on next generation injectable medicines. The company has entered collaborations with Repertoire Immune Medicines and Seamless Therapeutics to expand into autoimmune and hearing loss therapies. Lilly is rapidly scaling its U.S. manufacturing footprint using advanced technologies to support future product launches in weight loss and related therapies. Eli Lilly, trading at...",
    "url": "https://finnhub.io/api/news?id=c9864d9ceb0c973576e88aa231d516606c52427506dec666380d8abdaaab11a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770314972,
      "headline": "Eli Lilly Expands GLP-1 Capacity While Building Beyond Obesity And Diabetes",
      "id": 138367481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) is committing over $3.5b to a new manufacturing facility in Pennsylvania’s Lehigh Valley focused on next generation injectable medicines. The company has entered collaborations with Repertoire Immune Medicines and Seamless Therapeutics to expand into autoimmune and hearing loss therapies. Lilly is rapidly scaling its U.S. manufacturing footprint using advanced technologies to support future product launches in weight loss and related therapies. Eli Lilly, trading at...",
      "url": "https://finnhub.io/api/news?id=c9864d9ceb0c973576e88aa231d516606c52427506dec666380d8abdaaab11a9"
    }
  },
  {
    "ts": null,
    "headline": "The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short",
    "summary": "The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short",
    "url": "https://finnhub.io/api/news?id=7db8a736b1ec613f34eed5e13e3c311a98712dfa0350009df6fa7a78704fb96c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770314602,
      "headline": "The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short",
      "id": 138369426,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7db8a736b1ec613f34eed5e13e3c311a98712dfa0350009df6fa7a78704fb96c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Positives Outweigh The Concerns",
    "summary": "Eli Lilly and Company earnings beat lifts stock: revenue/EPS beat guidance, and the 2026 outlook looks strong, but watch Zepbound price cuts. Click for this LLY update.",
    "url": "https://finnhub.io/api/news?id=e4377796e607ff03748adcc3aa84add5e2e3f58e2478de07bc9aa56c98f9a9b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770312516,
      "headline": "Eli Lilly: Positives Outweigh The Concerns",
      "id": 138369249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411734128/image_1411734128.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company earnings beat lifts stock: revenue/EPS beat guidance, and the 2026 outlook looks strong, but watch Zepbound price cuts. Click for this LLY update.",
      "url": "https://finnhub.io/api/news?id=e4377796e607ff03748adcc3aa84add5e2e3f58e2478de07bc9aa56c98f9a9b2"
    }
  },
  {
    "ts": null,
    "headline": "This Healthcare Company Believes Its GLP-1 Pill Could Be \"Next in Line\" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.",
    "summary": "Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.",
    "url": "https://finnhub.io/api/news?id=8dac683ff721650cf455d02db579db0e041eb4694ab916220e76b85fa33b9a66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770311580,
      "headline": "This Healthcare Company Believes Its GLP-1 Pill Could Be \"Next in Line\" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.",
      "id": 138366073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.",
      "url": "https://finnhub.io/api/news?id=8dac683ff721650cf455d02db579db0e041eb4694ab916220e76b85fa33b9a66"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) Shares Are Getting Obliterated Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 7.4% in the morning session after the company discontinued three clinical pipeline assets, including a gene therapy for dementia acquired through a billion-dollar deal.",
    "url": "https://finnhub.io/api/news?id=9094307180aae0baa957a7f4d815c8ae1f358cdc4f33ef6063fa43447cdfbd7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770310569,
      "headline": "Why Eli Lilly (LLY) Shares Are Getting Obliterated Today",
      "id": 138366074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 7.4% in the morning session after the company discontinued three clinical pipeline assets, including a gene therapy for dementia acquired through a billion-dollar deal.",
      "url": "https://finnhub.io/api/news?id=9094307180aae0baa957a7f4d815c8ae1f358cdc4f33ef6063fa43447cdfbd7e"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Is Introducing a Cheaper Wegovy Copycat. Novo Nordisk Stock Falls.",
    "summary": "Hims & Hers’ new alternative to Novo Nordisk’s Wegovy pill will sell for $49 for the first month and $99 a month after that.",
    "url": "https://finnhub.io/api/news?id=42d991679eb55ebad3b47e20b0030932dd5f07cb2936a8c63288f4e91da0b33c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770310560,
      "headline": "Hims & Hers Is Introducing a Cheaper Wegovy Copycat. Novo Nordisk Stock Falls.",
      "id": 138366075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers’ new alternative to Novo Nordisk’s Wegovy pill will sell for $49 for the first month and $99 a month after that.",
      "url": "https://finnhub.io/api/news?id=42d991679eb55ebad3b47e20b0030932dd5f07cb2936a8c63288f4e91da0b33c"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Just Dropped",
    "summary": "Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.",
    "url": "https://finnhub.io/api/news?id=d5c351cdde9f95ca59995b44241047a088b619fe9c2e681d69843ff00d1e21e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770307689,
      "headline": "Why Eli Lilly Stock Just Dropped",
      "id": 138366076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.",
      "url": "https://finnhub.io/api/news?id=d5c351cdde9f95ca59995b44241047a088b619fe9c2e681d69843ff00d1e21e4"
    }
  },
  {
    "ts": null,
    "headline": "Hims Is Already Knocking Off Novo's Wegovy Pill — For Just $49 A Month",
    "summary": "Hims & Hers Health launched a compounded version of Novo Nordisk's already popular weight-loss pill on Thursday.",
    "url": "https://finnhub.io/api/news?id=88b07f067399b1eaaca05661be06274d16c9a8d2ac3f4aa3388502b584861c86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770306304,
      "headline": "Hims Is Already Knocking Off Novo's Wegovy Pill — For Just $49 A Month",
      "id": 138364444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health launched a compounded version of Novo Nordisk's already popular weight-loss pill on Thursday.",
      "url": "https://finnhub.io/api/news?id=88b07f067399b1eaaca05661be06274d16c9a8d2ac3f4aa3388502b584861c86"
    }
  },
  {
    "ts": null,
    "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
    "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines.",
    "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305054,
      "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
      "id": 138376237,
      "image": "https://image.cnbcfm.com/api/v1/image/108262460-1770383887859-gettyimages-2259525568-TRUMPRX_LAUNCH.jpeg?v=1770384067&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines. ",
      "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb"
    }
  },
  {
    "ts": null,
    "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
    "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303347,
      "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
      "id": 138364445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75"
    }
  },
  {
    "ts": null,
    "headline": "Hims launches $49 compounded copy of Wegovy weight-loss pill",
    "summary": "By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will start offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price",
    "url": "https://finnhub.io/api/news?id=147d7347e6be25769551f00ecd45f18e90c2ceef02bc1767224e5861b96e0128",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770302269,
      "headline": "Hims launches $49 compounded copy of Wegovy weight-loss pill",
      "id": 138364446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will start offering compounded copies of Novo Nordisk's new Wegovy weight-loss pill at an introductory price",
      "url": "https://finnhub.io/api/news?id=147d7347e6be25769551f00ecd45f18e90c2ceef02bc1767224e5861b96e0128"
    }
  },
  {
    "ts": null,
    "headline": "Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall",
    "summary": "Investing.com -- Hims and Hers Health (NYSE:HIMS) stock surged 19% on Thursday after the telehealth company announced it will offer compounded versions of Novo Nordisk’s (NYSE:NVO) new Wegovy pill at an introductory price of $49 per month, significantly undercutting the brand-name product.",
    "url": "https://finnhub.io/api/news?id=54d047536f8afeb655e8a7a773337fc24bb3bd4c589a0c0d493f2d5f88680705",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770302181,
      "headline": "Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall",
      "id": 138364447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Hims and Hers Health (NYSE:HIMS) stock surged 19% on Thursday after the telehealth company announced it will offer compounded versions of Novo Nordisk’s (NYSE:NVO) new Wegovy pill at an introductory price of $49 per month, significantly undercutting the brand-name product.",
      "url": "https://finnhub.io/api/news?id=54d047536f8afeb655e8a7a773337fc24bb3bd4c589a0c0d493f2d5f88680705"
    }
  },
  {
    "ts": null,
    "headline": "Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results",
    "summary": "Stock futures are mixed and have shown modest signs of stabilization after a sharp downturn in software and AI-related technology stocks yesterday, prompting some investors to treat the technology selloff that pressured equities broadly as a buying opportunity. Against that backdrop, defensive sectors and commodity-linked assets have drawn interest, particularly as gold reclaimed levels above $5,000 an ounce, reflecting continued demand for safe havens amid uncertainty. Claim 50% Off TipRanks Pr",
    "url": "https://finnhub.io/api/news?id=cfaad9cb9c8162fc497e630737dd9f08ad8a09c9963d03c6eb09d779786d0bd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300052,
      "headline": "Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results",
      "id": 138363701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock futures are mixed and have shown modest signs of stabilization after a sharp downturn in software and AI-related technology stocks yesterday, prompting some investors to treat the technology selloff that pressured equities broadly as a buying opportunity. Against that backdrop, defensive sectors and commodity-linked assets have drawn interest, particularly as gold reclaimed levels above $5,000 an ounce, reflecting continued demand for safe havens amid uncertainty. Claim 50% Off TipRanks Pr",
      "url": "https://finnhub.io/api/news?id=cfaad9cb9c8162fc497e630737dd9f08ad8a09c9963d03c6eb09d779786d0bd9"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall, Bitcoin Dives Below $70,000; Google AI Spending Stuns",
    "summary": "Google earnings were strong, but AI spending stunned. Bitcoin continues to dive while the stock market is deeply divided.",
    "url": "https://finnhub.io/api/news?id=14b53ee46546759401ae67634d29e62ca51b2811c2d7dbd3a24d649d5354d560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296942,
      "headline": "Dow Jones Futures Fall, Bitcoin Dives Below $70,000; Google AI Spending Stuns",
      "id": 138363452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Google earnings were strong, but AI spending stunned. Bitcoin continues to dive while the stock market is deeply divided.",
      "url": "https://finnhub.io/api/news?id=14b53ee46546759401ae67634d29e62ca51b2811c2d7dbd3a24d649d5354d560"
    }
  },
  {
    "ts": null,
    "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
    "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
    "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296280,
      "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
      "id": 138364449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
      "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772"
    }
  },
  {
    "ts": null,
    "headline": "Novo, Lilly sputter as Hims launches knockoff GLP-1 pill",
    "summary": "Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called an “unapproved, inauthentic, and untested knockoff” of its fast-selling medication.",
    "url": "https://finnhub.io/api/news?id=3c6aad0f4dc0548e8180d4585e068ca564eb129f585cc0c6d1542fbef1f8dff4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770294120,
      "headline": "Novo, Lilly sputter as Hims launches knockoff GLP-1 pill",
      "id": 138366077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called an “unapproved, inauthentic, and untested knockoff” of its fast-selling medication.",
      "url": "https://finnhub.io/api/news?id=3c6aad0f4dc0548e8180d4585e068ca564eb129f585cc0c6d1542fbef1f8dff4"
    }
  },
  {
    "ts": null,
    "headline": "US Stock Market Today S&P 500 Futures Nudge Higher As Rate Jitters Linger",
    "summary": "The Morning Bull - US Market Morning Update Thursday, Feb, 5 2026 US stock futures are pointing slightly higher this morning, with contracts tied to the S&P 500 and Nasdaq 100 up around 0.1% to 0.3%, as investors weigh a mixed set of signals on growth and interest rates. ADP private payrolls showed just 22,000 new jobs in January 2026, hinting that hiring is slowing, while the ISM Services PMI held at 53.8, meaning services businesses are still growing and facing rising input costs. At the...",
    "url": "https://finnhub.io/api/news?id=a322468a0a67473c16920ce11d318a9d49c4165c2f3313820b117929134b4d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770286507,
      "headline": "US Stock Market Today S&P 500 Futures Nudge Higher As Rate Jitters Linger",
      "id": 138362668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Morning Bull - US Market Morning Update Thursday, Feb, 5 2026 US stock futures are pointing slightly higher this morning, with contracts tied to the S&P 500 and Nasdaq 100 up around 0.1% to 0.3%, as investors weigh a mixed set of signals on growth and interest rates. ADP private payrolls showed just 22,000 new jobs in January 2026, hinting that hiring is slowing, while the ISM Services PMI held at 53.8, meaning services businesses are still growing and facing rising input costs. At the...",
      "url": "https://finnhub.io/api/news?id=a322468a0a67473c16920ce11d318a9d49c4165c2f3313820b117929134b4d44"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill",
    "summary": "Hims said it would sell a copy of the newly launched weight loss pill for $49, far less than the $149 Novo sells the branded pill for.",
    "url": "https://finnhub.io/api/news?id=9309f54d7c952e7a3b9cbeb5acfd1e3e1adb15cb11e97517ca4a581d373e47b2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770282854,
      "headline": "Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill",
      "id": 138365491,
      "image": "https://image.cnbcfm.com/api/v1/image/108261298-17702146372026-02-04t141023z_346821360_rc20fjakic3w_rtrmadp_0_novo-nordisk-results.jpeg?v=1770311641&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Hims said it would sell a copy of the newly launched weight loss pill for $49, far less than the $149 Novo sells the branded pill for.",
      "url": "https://finnhub.io/api/news?id=9309f54d7c952e7a3b9cbeb5acfd1e3e1adb15cb11e97517ca4a581d373e47b2"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?",
    "summary": "Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.",
    "url": "https://finnhub.io/api/news?id=a4c6ba9420fbb92a73f9070ef622dca3fc01421c28d0a54b630b992edf295649",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770282300,
      "headline": "Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?",
      "id": 138362074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.",
      "url": "https://finnhub.io/api/news?id=a4c6ba9420fbb92a73f9070ef622dca3fc01421c28d0a54b630b992edf295649"
    }
  },
  {
    "ts": null,
    "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
    "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
    "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770282000,
      "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
      "id": 138362075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
      "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company Q4 Earnings Call Highlights",
    "summary": "Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, and an expanding late-stage pipeline during the company’s Q4 2025 earnings conference call. Management also outlined 2026 financial guidance that anticipates higher revenue d",
    "url": "https://finnhub.io/api/news?id=8b9c8ebe25b8153e9da5e157f1f60a3aca185f44612eb5e85b3c637179c7856e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770280018,
      "headline": "Eli Lilly and Company Q4 Earnings Call Highlights",
      "id": 138362076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, and an expanding late-stage pipeline during the company’s Q4 2025 earnings conference call. Management also outlined 2026 financial guidance that anticipates higher revenue d",
      "url": "https://finnhub.io/api/news?id=8b9c8ebe25b8153e9da5e157f1f60a3aca185f44612eb5e85b3c637179c7856e"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma’s most valuable up-and-coming GLP-1s",
    "summary": "Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.",
    "url": "https://finnhub.io/api/news?id=b57a6a83ce190955e2321ca2fcc05e223961ff17b54907fa35de64fafa5ec66f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770278400,
      "headline": "Big Pharma’s most valuable up-and-coming GLP-1s",
      "id": 138363533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.",
      "url": "https://finnhub.io/api/news?id=b57a6a83ce190955e2321ca2fcc05e223961ff17b54907fa35de64fafa5ec66f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Skyrockets as Profits Soar 95%",
    "summary": "We recently published 10 Stocks With Monster Gains. Eli Lilly and Company (NYSE:LLY) was one of the top performers on Wednesday. Eli Lilly soared by 10.33 percent on Wednesday to close at $1,107.12 apiece after profits last year nearly doubled on the back of strong sales from Zepbound and Mounjaro, alongside a 23 percent revenue […]",
    "url": "https://finnhub.io/api/news?id=6c4d62597fcafaad8ab4e0e537b09c5de40683e4d0655de9cdc2a99bbee88d06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770276504,
      "headline": "Eli Lilly (LLY) Skyrockets as Profits Soar 95%",
      "id": 138361535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Monster Gains. Eli Lilly and Company (NYSE:LLY) was one of the top performers on Wednesday. Eli Lilly soared by 10.33 percent on Wednesday to close at $1,107.12 apiece after profits last year nearly doubled on the back of strong sales from Zepbound and Mounjaro, alongside a 23 percent revenue […]",
      "url": "https://finnhub.io/api/news?id=6c4d62597fcafaad8ab4e0e537b09c5de40683e4d0655de9cdc2a99bbee88d06"
    }
  },
  {
    "ts": null,
    "headline": "LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 4.8% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=bea3dc7175d1261e63b56a5c5fa6828161eb726745b6b40edaa40d34be168778",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770269908,
      "headline": "LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance",
      "id": 138362669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 4.8% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=bea3dc7175d1261e63b56a5c5fa6828161eb726745b6b40edaa40d34be168778"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly (LLY) Still Attractive After Obesity Drug Headlines And A US$1,107 Share Price?",
    "summary": "If you are wondering whether Eli Lilly's share price already reflects what you are hearing about weight loss and other treatments, or if there could still be value on the table, this article walks through what the numbers are saying right now. The stock last closed at US$1,107.12, with returns of 8.1% over 7 days, 6.3% over 30 days, 2.5% year to date, 32.4% over 1 year, and a very large gain over 5 years. Recent headlines have focused heavily on Eli Lilly's obesity and diabetes drug...",
    "url": "https://finnhub.io/api/news?id=2aeec9758ca1dd738194e1a3f5e45f0465ba861bdb07db3da3d40c2219009eb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770266221,
      "headline": "Is Eli Lilly (LLY) Still Attractive After Obesity Drug Headlines And A US$1,107 Share Price?",
      "id": 138361022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Eli Lilly's share price already reflects what you are hearing about weight loss and other treatments, or if there could still be value on the table, this article walks through what the numbers are saying right now. The stock last closed at US$1,107.12, with returns of 8.1% over 7 days, 6.3% over 30 days, 2.5% year to date, 32.4% over 1 year, and a very large gain over 5 years. Recent headlines have focused heavily on Eli Lilly's obesity and diabetes drug...",
      "url": "https://finnhub.io/api/news?id=2aeec9758ca1dd738194e1a3f5e45f0465ba861bdb07db3da3d40c2219009eb4"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall; Google Beats Views, Huge AI Spending Stuns",
    "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
    "url": "https://finnhub.io/api/news?id=90acd7f61c737a1403d80c433737b5483f9b9902f2e097ee23b8d588ebbdc191",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770263614,
      "headline": "Dow Jones Futures Fall; Google Beats Views, Huge AI Spending Stuns",
      "id": 138360472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
      "url": "https://finnhub.io/api/news?id=90acd7f61c737a1403d80c433737b5483f9b9902f2e097ee23b8d588ebbdc191"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Soared Today",
    "summary": "The healthcare giant gained nearly $100 billion in market value.",
    "url": "https://finnhub.io/api/news?id=9265d7f3d96ccb4c0d2dbbd013113ae99d11dc581bb0dc69dc937a52bf2a6c4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770262714,
      "headline": "Why Eli Lilly Stock Soared Today",
      "id": 138360504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare giant gained nearly $100 billion in market value.",
      "url": "https://finnhub.io/api/news?id=9265d7f3d96ccb4c0d2dbbd013113ae99d11dc581bb0dc69dc937a52bf2a6c4f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation",
    "summary": "Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation",
    "url": "https://finnhub.io/api/news?id=6884b57b165f706387ffcb7ea63bf6d1d2b4e4ff8eb723ad206455359efff971",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770260019,
      "headline": "Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation",
      "id": 138361526,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6884b57b165f706387ffcb7ea63bf6d1d2b4e4ff8eb723ad206455359efff971"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Google Beats Views, Huge AI Spending Stuns",
    "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
    "url": "https://finnhub.io/api/news?id=2bcb73da43d86c6d77106bf323b02f5036ddcc85d94a425b5da95304fc5fd897",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770255599,
      "headline": "Dow Jones Futures: Google Beats Views, Huge AI Spending Stuns",
      "id": 138359998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
      "url": "https://finnhub.io/api/news?id=2bcb73da43d86c6d77106bf323b02f5036ddcc85d94a425b5da95304fc5fd897"
    }
  }
]